## 권고사항

6. 항바이러스제 치료 종료 후 1년간은 간기능검사, real-time PCR법에 의한 혈청 HBV DNA 측정을 1-3개월 간격으로 하고 HBeAg, anti-HBe는 3-6개월 간격으로 검사할 것을 고려한다. 1년이 경과한 후에는 간기능검사, real-time PCR법에 의한 혈청 HBV DNA 측정을 3-6개월 간격으로 시행하는 재발 추적관찰을 고려한다 (C1).
7. 간세포암종의 조기발견을 위해 복부초음파검사와 혈청알파태아단백검사를 정기적으로 시행한다 (A1).

Table 6. Nucleos(t)ide analogues dosage adjustment for adult patients with altered creatinine clearance

| Creatinine clearance (ml/min)a | Recommended dose (NA naavi)                       | Recommended dose (Lamivudine refractory/resistant) |
| :----------------------------- | :------------------------------------------------ | :------------------------------------------------- |
| **Nucleoside Analogues**       |                                                   |                                                    |
| **Lamivudine**                 |                                                   |                                                    |
| ≥ 50                           | 100 mg q 24hrs                                    |                                                    |
| 30-49                          | 100 mg first dose, then 50 mg q 24hrs             |                                                    |
| 15-29                          | 100 mg first dose, then 25 mg q 24hrs             |                                                    |
| 5-14                           | 35 mg first dose, then 15 mg q 24hrs              |                                                    |
| <5                             | 35 mg first dose, then 10 mg q 24hrs              |                                                    |
| **Telbivudine**                |                                                   |                                                    |
| ≥ 50                           | 600 mg q 24hrs                                    |                                                    |
| 30-49                          | 600 mg q 48hrs                                    |                                                    |
| <30 (not requiring dialysis)   | 600 mg q 72hrs                                    |                                                    |
| End-stage renal diseaseb       | 600 mg q 96hrs                                    |                                                    |
| **Entecavir**                  | **NA naavi**                                      | **Lamivudine refractory/resistant**                |
| ≥ 50                           | 0.5 mg q 24hrs                                    | 1 mg q 24hrs                                       |
| 30-49                          | 0.25 mg q 24hrs or 0.5mg q 48hrs                  | 0.5 mg q 24hrs or 1mg q 48hrs                      |
| 10-29                          | 0.15 mg q 24hrs or 0.5mg q 72hrs                  | 0.3 mg q 24hrs or 1 mg q 72hrs                     |
| <10 or hemodialysisb or continuous ambulatory peritoneal dialysis | 0.05 mg q 24hrs or 0.5mg q 7days                  | 0.1 mg q 24hrs or 1mg q 7days                      |
| **Nucleotide Analogues**       |                                                   |                                                    |
| **Adefovir**                   |                                                   |                                                    |
| ≥ 50                           | 10 mg q 24hrs                                     |                                                    |
| 20-49                          | 10 mg q 48hrs                                     |                                                    |
| 10-19                          | 10 mg q 72hrs                                     |                                                    |
| <10                            | No recommendation                                 |                                                    |
| Hemodialysisb                  | 10 mg q 7days following dialysis                  |                                                    |
| **Tenofovir**                  |                                                   |                                                    |
| ≥ 50                           | 300mg q 24 hrs                                    |                                                    |
| 30-49                          | 300mg q 48 hrs                                    |                                                    |
| 10-29                          | 300mg q 72-96 hrs                                 |                                                    |
| <10 with dialysisc             | 300mg q 7days or after a total of approximately 12 hrs of dialysis |                                                    |
| <10 without dialysis           | No recommendation                                 |                                                    |

a. Calculated using ideal (lean) body weight.
b. Administer after hemodialysis
c. Generally once a weekly assuming three hemodialysis sessions a week of approximately 4 hours duration. Administer following completion of dialysis

<PAGE>60